Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Individual clinical outcomes

From: Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety

Patient Best response (RECIST) Time to progression (days) First site of progression Salvage therapy Time to death (days)
1 SD 189 Local + distant None 254
2 PR 317 Local Capecitabine (maintenance); Radiation 440
5 SD 470 Distant None 490
6 SD 228 Distant FOLFOX 397
7 SD 176 Distant Erlotinib with gemcitabine 382
8 PR 450 Local None 462
9 SD 251 Distant Capecitabine, FOLFOX+ABT888 618
10 PD 66 Local None 135
13 SD 168 Distant None 257
14 SD 121 Distant Progressed on gemcitabine, switched to lapatinib + capecitabine 305